Skip to main
DXCM
DXCM logo

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 52%
Buy 33%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

DexCom has demonstrated robust growth in both domestic and international markets, with international revenue increasing by 22% year-over-year, driven primarily by recent coverage wins in France and Canada. The company has effectively expanded its contribution from Type 2 diabetes (T2D) customers, achieving a 21% increase in domestic revenue, reinforcing its strong market penetration. Additionally, DexCom's upward revised sales guidance for the full year, now projected at $4.630B to $4.650B, coupled with favorable trends in remote monitoring and patient accessibility, indicates a promising trajectory for sustainable growth moving forward.

Bears say

DexCom's lowered profitability outlook and weak gross margins are indicative of underlying challenges within the company, as highlighted by the first declining quarter of new patient additions in some time. The revenue growth for sensors, while positive, was offset by a significant decline in hardware sales and concerns regarding quality issues, which may have adverse effects on future performance. Additionally, competitive pressures and operational risks, including escalating pricing competition and supply chain disruptions, further contribute to a negative outlook for DexCom’s stock.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 52% of analysts recommend a Strong Buy, 33% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.